Product Description
Boehringer Ingelheim is developing oral BI 1595043 in an unknown indication.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Boehringer Ingelheim
Company Location: Europe
Company Founding Year: 1885
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04789304 |
NCT04789304 | P1 |
Completed |
Healthy Volunteers |
2022-01-14 |
50% |
2024-02-22 |
Primary Endpoints |
NCT04789291 |
NCT04789291 | P1 |
Completed |
Healthy Volunteers |
2021-08-07 |
50% |
2024-02-23 |
Primary Endpoints |
NCT04439838 |
NCT04439838 | P1 |
Completed |
Healthy Volunteers |
2021-03-19 |
50% |
2024-02-22 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|